HR Execs on the Move

Kurome Therapeutics

www.kurometherapeutics.com

 
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Jan Rosenbaum
President, Chief Executive Officer Profile

Similar Companies

ALK-Abello

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is primarily engaged in the development of pharmaceutical products that target the cause of allergy. The Company is focused on allergy vaccination. Its product

BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements.

DMI Services

DMI Services is a Lafayette, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Human Genome Sciences

Human Genome Sciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Locus Biosciences

Locus Biosciences` novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating a small strand of RNA called a CRISPR RNA, which matches a DNA sequence specific to a given invader. If the CRISPR RNA is matched to a complementary DNA sequence, the Cas proteins will cleave the invading DNA.